News & Media
|Hemostemix to Present at Phacilitate Cell & Gene Therapy World 2016|
|Jan 21 2016 -
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM) (OTCQX: HMTXF), a clinical-stage autologous cell-therapy company, announced today that Dr. Elmar Burchardt, the Company’s president and CEO, is an invited speaker at Phacilitate Cell & Gene Therapy World 2016 to be held January 25–27 in Washington, D.C. On Monday, January 25, at 12:30 p.m. EST, Dr. Burchardt will present “Developing a Cell Therapy for Critical Limb Ischemia (CLI): A Few Potholes from the Past and Navigating the Road Ahead,” which focuses on the Hemostemix lead product ACP-01 and its international, multicenter, phase-2 clinical trial for patients with CLI.
Now in its 12th year, Phacilitate Cell & Gene Therapy World draws more than 190 expert speakers and 750 leading cell and gene-therapy executive decision makers, thought leaders, and technology implementers for networking, financing, R&D, manufacturing, and commercialization opportunities. In 2015, attendees represented 256 organizations from 22 countries. For more information about the conference, visit bioleaders-forum.com.
The ongoing Hemostemix phase-2 clinical trial investigates the safety and efficacy of the Company's lead product, ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI, a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. About half of CLI patients either die or require amputation of the affected limb within one year of diagnosis. Demand for a treatment is on the rise, as CLI predominantly affects the growing population aged 50 and older.
The phase-2 trial targets a participant’s diseased tissue with proprietary cells that are grown from his or her blood and capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada. The Company has recently received FDA clearance to commence clinical trials in the United States.
For more information, email email@example.com.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.